| Cash Flow | 2026-02-28 | 2025-08-31 | 2025-05-31 |
|---|---|---|---|
| Net income (loss) | NaN | -31,814 | 51,395 |
| Depreciation | NaN | NaN | 3,775 |
| Amortization | NaN | NaN | 7,251 |
| Impairment expenses | NaN | NaN | 3,463 |
| Due to related party | NaN | -3,500 | NaN |
| Changes in other assets | NaN | NaN | 50,079 |
| Due to shareholder | NaN | 0 | NaN |
| Increase in accounts receivable | NaN | NaN | -11,500 |
| Interest receivable | NaN | 0 | NaN |
| Accrued interest | NaN | 0 | -436 |
| Accounts receivable | NaN | 0 | NaN |
| Account payable and accrued expenses | NaN | 3,564 | -1,211 |
| Advances from related parties | NaN | 28,250 | -31,058 |
| Net cash provided by (used in) operating activities | NaN | 3,500 | -4,528 |
| Equipment, net | NaN | 0 | NaN |
| Intangibles, net | NaN | 0 | NaN |
| Net cash provided by (used in) investing activities | NaN | 0 | 0 |
| Additional paid-in capital | NaN | -3,500 | NaN |
| Proceeds from sale of common stock | NaN | NaN | 0 |
| Proceeds from note payable others | NaN | 0 | NaN |
| Apic | NaN | NaN | 3,500 |
| Proceeds from note payable related party | NaN | 0 | NaN |
| Accrued interest | NaN | 0 | 0 |
| Net cash provided by financing activities | NaN | -3,500 | 3,500 |
| Increase (decrease) in cash and equivalents | 0 | 0 | -1,028 |
| Cash and equivalents at beginning of the period | 0 | 0 | 1,028 |
| Cash and equivalents at end of the period | 0 | 0 | 0 |
Exousia Bio, Inc. (LMMY)
Exousia Bio, Inc. (LMMY)